http://hl7.org/fhir/uv/ebm/PublicationRecord/179627
type: PublicationRecord
resource definition: 1.0
resource definition: .0
node role: treeRoot
id:
  v: 179627
meta:
  version id:
    v: 21
  last updated:
    v: 2025-10-13T12:34:35.118Z
  profile:
    v: http://hl7.org/fhir/uv/ebm/StructureDefinition/journal-article-citation
    l: journal-article-citation
language:
  v: en
text:
  status:
    v: extensions
  div:
    v: Generated Narrative: PublicationRecord 179627 version: 21; Last updated: 2025-10-13 12:34:35+0000 Profile: JournalArticleCitation ArtifactPublicationStatus: Active url: https://fevir.net/resources/PublicationRecord/179627 identifier: FEvIR Object Identifier/179627, https://pubmed.ncbi.nlm.nih.gov/19091394 title: 19091394 Endocrine treatment, with or without radiotherapy, in locally advanced prostate cancer (SPCG-7/SFUO-3): an open randomised phase III trial. status: Active author: Computable Publishing®: MEDLINE-to-FEvIR Converter: publisher: Computable Publishing LLC contact: support@computablepublishing.com description: This Citation Resource is referenced in an example for the EBMonFHIR Implementation Guide. UseContexts - Code Value[x] * Citation Classification Type: fevir-platform-use (FEvIR Platform Use) Medline Base copyright: https://creativecommons.org/licenses/by-nc-sa/4.0/ approvalDate: 2009-02-05 lastReviewDate: 2022-03-30 classification type: Citation Source classifier: MEDLINE classification type: MEDLINE Citation Owner classifier: National Library of Medicine, Index Section currentState: Medline Citation Status of Medline, PubMed PublicationStatus of ppublish statusDate activity: PubMed Pubstatus of Entrez period: ?? --> 2008-12-19 09:00:00+0000 statusDate activity: PubMed Pubstatus of Pubmed period: ?? --> 2008-12-19 09:00:00+0000 statusDate activity: PubMed Pubstatus of Medline period: ?? --> 2009-02-06 09:00:00+0000 citedArtifact identifier: https://pubmed.ncbi.nlm.nih.gov/19091394, https://doi.org/10.1016/S0140-6736(08)61815-2, pii/S0140-6736(08)61815-2 relatedIdentifier: ISRCTN01534787 Titles - Type Language Text * Primary title English Endocrine treatment, with or without radiotherapy, in locally advanced prostate cancer (SPCG-7/SFUO-3): an open randomised phase III trial. Abstracts - Type Text * Primary human use BACKGROUND: Several studies have shown the efficacy of endocrine therapy in combination with radiotherapy in high-risk prostate cancer…
contained: Practitioner
  id:
    v: contributor0
  name:
    family:
      v: Widmark
    given:
      v: Anders
contained: Practitioner
  id:
    v: contributor1
  name:
    family:
      v: Klepp
    given:
      v: Olbjørn
contained: Practitioner
  id:
    v: contributor2
  name:
    family:
      v: Solberg
    given:
      v: Arne
contained: Practitioner
  id:
    v: contributor3
  name:
    family:
      v: Damber
    given:
      v: Jan-Erik
contained: Practitioner
  id:
    v: contributor4
  name:
    family:
      v: Angelsen
    given:
      v: Anders
contained: Practitioner
  id:
    v: contributor5
  name:
    family:
      v: Fransson
    given:
      v: Per
contained: Practitioner
  id:
    v: contributor6
  name:
    family:
      v: Lund
    given:
      v: Jo-Asmund
contained: Practitioner
  id:
    v: contributor7
  name:
    family:
      v: Tasdemir
    given:
      v: Ilker
contained: Practitioner
  id:
    v: contributor8
  name:
    family:
      v: Hoyer
    given:
      v: Morten
contained: Practitioner
  id:
    v: contributor9
  name:
    family:
      v: Wiklund
    given:
      v: Fredrik
contained: Practitioner
  id:
    v: contributor10
  name:
    family:
      v: Fosså
    given:
      v: Sophie D
contained: Organization
  id:
    v: contributor11
  name:
    v: Scandinavian Prostate Cancer Group Study 7
contained: Organization
  id:
    v: contributor12
  name:
    v: Swedish Association for Urological Oncology 3
contained: ArtifactAssessment
  id:
    v: meshHeading0
  artifact: Reference
    l: #
    reference:
      v: #
    type:
      v: PublicationRecord
      l: PublicationRecord
  content:
    type:
      text:
        v: components (if present) include qualifier codings
    classifier: D000368
    free to share:
      v: true
  content:
    type:
      text:
        v: components (if present) include qualifier codings
    classifier: D000726
    free to share:
      v: true
    component:
      classifier: Q000627
  content:
    type:
      text:
        v: components (if present) include qualifier codings
    classifier: D003131
    free to share:
      v: true
  content:
    type:
      text:
        v: components (if present) include qualifier codings
    classifier: D005485
    free to share:
      v: true
    component:
      classifier: Q000627
  content:
    type:
      text:
        v: components (if present) include qualifier codings
    classifier: D006801
    free to share:
      v: true
  content:
    type:
      text:
        v: components (if present) include qualifier codings
    classifier: D008297
    free to share:
      v: true
  content:
    type:
      text:
        v: components (if present) include qualifier codings
    classifier: D011468
    free to share:
      v: true
  content:
    type:
      text:
        v: components (if present) include qualifier codings
    classifier: D011471
    free to share:
      v: true
    component:
      classifier: Q000188
    component:
      classifier: Q000401
    component:
      classifier: Q000532
  content:
    type:
      text:
        v: components (if present) include qualifier codings
    classifier: D012720
    free to share:
      v: true

v: mesh-heading

v: MeSH heading

v: D000368

v: Aged

v: false

v: qualifier

v: is not a major topic

v: mesh-heading

v: MeSH heading

v: D000726

v: Androgen Antagonists

v: false

v: qualifier

v: is not a major topic

v: qualifier

system:
  v: https://www.nlm.nih.gov/mesh
  l: mesh
code:
  v: Q000627
display:
  v: therapeutic use

text:
  v: is Major topic

coding:
  system:
    v: http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl
    l: Thesaurus.owl
  code:
    v: C49488
  display:
    v: Yes

v: mesh-heading

v: MeSH heading

v: D003131

v: Combined Modality Therapy

v: false

v: qualifier

v: is not a major topic

v: mesh-heading

v: MeSH heading

v: D005485

v: Flutamide

v: false

v: qualifier

v: is not a major topic

v: qualifier

system:
  v: https://www.nlm.nih.gov/mesh
  l: mesh
code:
  v: Q000627
display:
  v: therapeutic use

text:
  v: is Major topic

coding:
  system:
    v: http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl
    l: Thesaurus.owl
  code:
    v: C49488
  display:
    v: Yes

v: mesh-heading

v: MeSH heading

v: D006801

v: Humans

v: false

v: qualifier

v: is not a major topic

v: mesh-heading

v: MeSH heading

v: D008297

v: Male

v: false

v: qualifier

v: is not a major topic

v: mesh-heading

v: MeSH heading

v: D011468

v: Prostatectomy

v: false

v: qualifier

v: is not a major topic

v: mesh-heading

v: MeSH heading

v: D011471

v: Prostatic Neoplasms

v: false

v: qualifier

v: is not a major topic

v: qualifier

system:
  v: https://www.nlm.nih.gov/mesh
  l: mesh
code:
  v: Q000188
display:
  v: drug therapy

text:
  v: is Major topic

coding:
  system:
    v: http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl
    l: Thesaurus.owl
  code:
    v: C49488
  display:
    v: Yes

v: qualifier

system:
  v: https://www.nlm.nih.gov/mesh
  l: mesh
code:
  v: Q000401
display:
  v: mortality

text:
  v: is Major topic

coding:
  system:
    v: http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl
    l: Thesaurus.owl
  code:
    v: C49487
  display:
    v: No

v: qualifier

system:
  v: https://www.nlm.nih.gov/mesh
  l: mesh
code:
  v: Q000532
display:
  v: radiotherapy

text:
  v: is Major topic

coding:
  system:
    v: http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl
    l: Thesaurus.owl
  code:
    v: C49488
  display:
    v: Yes

v: mesh-heading

v: MeSH heading

v: D012720

v: Severity of Illness Index

v: false

type:
  text:
    v: qualifier
classifier:
  text:
    v: is not a major topic

type:
  coding:
    system:
      v: http://terminology.hl7.org/CodeSystem/cited-artifact-classification-type
      l: cited-artifact-classification-type
    code:
      v: mesh-heading
    display:
      v: MeSH heading
  text:
    v: components (if present) include qualifier codings
classifier: D016019
  coding:
    system:
      v: https://www.nlm.nih.gov/mesh
      l: mesh
    code:
      v: D016019
    display:
      v: Survival Analysis
    user selected:
      v: false
free to share:
  v: true
component:
  type:
    text:
      v: qualifier
  classifier:
    text:
      v: is not a major topic

url:
  v: http://hl7.org/fhir/uv/ebm/StructureDefinition/artifact-publication-status
  l: artifact-publication-status
value: CodeableConcept
  coding:
    system:
      v: http://terminology.hl7.org/CodeSystem/cited-artifact-status-type
      l: cited-artifact-status-type
    code:
      v: active
    display:
      v: Active

type:
  coding:
    system:
      v: http://terminology.hl7.org/CodeSystem/v2-0203
      l: v2-0203
    code:
      v: ACSN
    display:
      v: Accession ID
  text:
    v: FEvIR Object Identifier
system:
  v: https://fevir.net/FOI
  l: FOI
value:
  v: 179627
assigner:
  display:
    v: Computable Publishing LLC

system:
  v: https://pubmed.ncbi.nlm.nih.gov
  l: pubmed.ncbi.nlm.nih.gov
value:
  v: 19091394

v: 19091394 Endocrine treatment, with or without radiotherapy, in locally advanced prostate cancer (SPCG-7/SFUO-3): an open randomised phase III trial.

v: active

name:
  v: Computable Publishing®: MEDLINE-to-FEvIR Converter

v: Computable Publishing LLC

telecom:
  system:
    v: email

v: This Citation Resource is referenced in an example for the EBMonFHIR Implementation Guide.

code:
  system:
    v: http://terminology.hl7.org/CodeSystem/citation-classification-type
    l: citation-classification-type
  code:
    v: fevir-platform-use
  display:
    v: FEvIR Platform Use
value: CodeableConcept
  coding:
    system:
      v: http://terminology.hl7.org/CodeSystem/citation-artifact-classifier
      l: citation-artifact-classifier
    code:
      v: medline-base
    display:
      v: Medline Base
    user selected:
      v: false

v: 2009-02-05

v: 2022-03-30

type:
  coding:
    system:
      v: http://terminology.hl7.org/CodeSystem/citation-classification-type
      l: citation-classification-type
    code:
      v: citation-source
    display:
      v: Citation Source
classifier:
  text:
    v: MEDLINE

type:
  coding:
    system:
      v: http://terminology.hl7.org/CodeSystem/citation-classification-type
      l: citation-classification-type
    code:
      v: medline-owner
    display:
      v: MEDLINE Citation Owner
classifier:
  coding:
    system:
      v: https://www.nlm.nih.gov/bsd/licensee/elements_descriptions.html#owner_value
      l: owner value
    code:
      v: NLM
    display:
      v: National Library of Medicine, Index Section
    user selected:
      v: false

coding:
  system:
    v: http://hl7.org/fhir/uv/ebm-incubator/CodeSystem/publicationrecord-status-type
    l: publicationrecord-status-type
  code:
    v: medline-medline
  display:
    v: Medline Citation Status of Medline

coding:
  system:
    v: http://hl7.org/fhir/uv/ebm-incubator/CodeSystem/publicationrecord-status-type
    l: publicationrecord-status-type
  code:
    v: pubmed-publication-status-ppublish
  display:
    v: PubMed PublicationStatus of ppublish

activity:
  coding:
    system:
      v: http://hl7.org/fhir/uv/ebm-incubator/CodeSystem/publicationrecord-status-type
      l: publicationrecord-status-type
    code:
      v: pubmed-pubstatus-entrez
    display:
      v: PubMed Pubstatus of Entrez
period:
  end:
    v: 2008-12-19T09:00:00.000Z

activity:
  coding:
    system:
      v: http://hl7.org/fhir/uv/ebm-incubator/CodeSystem/publicationrecord-status-type
      l: publicationrecord-status-type
    code:
      v: pubmed-pubstatus-pubmed
    display:
      v: PubMed Pubstatus of Pubmed
period:
  end:
    v: 2008-12-19T09:00:00.000Z

activity:
  coding:
    system:
      v: http://hl7.org/fhir/uv/ebm-incubator/CodeSystem/publicationrecord-status-type
      l: publicationrecord-status-type
    code:
      v: pubmed-pubstatus-medline
    display:
      v: PubMed Pubstatus of Medline
period:
  end:
    v: 2009-02-06T09:00:00.000Z

identifier:
  system:
    v: https://pubmed.ncbi.nlm.nih.gov
    l: pubmed.ncbi.nlm.nih.gov
  value:
    v: 19091394
identifier:
  system:
    v: https://doi.org
    l: doi.org
  value:
    v: 10.1016/S0140-6736(08)61815-2
identifier:
  type:
    coding:
      system:
        v: http://terminology.hl7.org/CodeSystem/v2-0203
        l: v2-0203
      code:
        v: ACSN
      display:
        v: Accession ID
    text:
      v: pii
  value:
    v: S0140-6736(08)61815-2
related identifier:
  value:
    v: ISRCTN01534787
  assigner:
    display:
      v: ISRCTN
title:
  type:
    coding:
      system:
        v: http://terminology.hl7.org/CodeSystem/title-type
        l: title-type
      code:
        v: primary
      display:
        v: Primary title
  language:
    v: en
  text:
    v: Endocrine treatment, with or without radiotherapy, in locally advanced prostate cancer (SPCG-7/SFUO-3): an open randomised phase III trial.
abstract:
  type:
    coding:
      system:
        v: http://terminology.hl7.org/CodeSystem/cited-artifact-abstract-type
        l: cited-artifact-abstract-type
      code:
        v: primary-human-use
      display:
        v: Primary human use
  text:
    v: **BACKGROUND:** Several studies have shown the efficacy of endocrine therapy in combination with radiotherapy in high-risk prostate cancer. To assess the effect of radiotherapy, we did an open phase III study comparing endocrine therapy with and without local radiotherapy, followed by castration on progression. **METHODS:** This randomised trial included men from 47 centres in Norway, Sweden, and Denmark. Between February, 1996, and December, 2002, 875 patients with locally advanced prostate cancer (T3; 78%; PSA<70; N0; M0) were centrally randomly assigned by computer to endocrine treatment alone (3 months of total androgen blockade followed by continuous endocrine treatment using flutamide; 439 patients), or to the same endocrine treatment combined with radiotherapy (436 patients). The primary endpoint was prostate-cancer-specific survival, and analysis was by intention to treat. This study is registered as an international standard randomised controlled trial, number ISRCTN01534787. **FINDINGS:** After a median follow-up of 7.6 years, 79 men in the endocrine alone group and 37 men in the endocrine plus radiotherapy group had died of prostate cancer. The cumulative incidence at 10 years for prostate-cancer-specific mortality was 23.9% in the endocrine alone group and 11.9% in the endocrine plus radiotherapy group (difference 12.0%, 95% CI 4.9-19.1%), for a relative risk of 0.44 (0.30-0.66). At 10 years, the cumulative incidence for overall mortality was 39.4% in the endocrine alone group and 29.6% in the endocrine plus radiotherapy group (difference 9.8%, 0.8-18.8%), for a relative risk of 0.68 (0.52-0.89). Cumulative incidence at 10 years for PSA recurrence was substantially higher in men in the endocrine-alone group (74.7%vs 25.9%, p<0.0001; HR 0.16; 0.12-0.20). After 5 years, urinary, rectal, and sexual problems were slightly more frequent in the endocrine plus radiotherapy group. **INTERPRETATION:** In patients with locally advanced or high-risk local prostate …
relates to:
  type:
    coding:
      system:
        v: http://terminology.hl7.org/CodeSystem/artifact-relationship-type
        l: artifact-relationship-type
      code:
        v: correction-in
      display:
        v: Correction In
  classifier: D016425
    coding:
      system:
        v: https://www.nlm.nih.gov/mesh
        l: mesh
      code:
        v: D016425
      display:
        v: Published Erratum
      user selected:
        v: false
  citation:
    v: Lancet. 2009 Apr 4;373(9670):1174
relates to:
  type:
    coding:
      system:
        v: http://terminology.hl7.org/CodeSystem/artifact-relationship-type
        l: artifact-relationship-type
      code:
        v: comment-in
      display:
        v: Has Comment In
  classifier: D016420
    coding:
      system:
        v: https://www.nlm.nih.gov/mesh
        l: mesh
      code:
        v: D016420
      display:
        v: Comment
      user selected:
        v: false
  citation:
    v: Lancet. 2009 Jan 24;373(9660):274-6. doi: 10.1016/S0140-6736(08)61816-4.
  target: Uri
    v: https://pubmed.ncbi.nlm.nih.gov/19091392/
    l: https://pubmed.ncbi.nlm.nih.gov/19091392/
relates to:
  type:
    coding:
      system:
        v: http://terminology.hl7.org/CodeSystem/artifact-relationship-type
        l: artifact-relationship-type
      code:
        v: comment-in
      display:
        v: Has Comment In
  classifier: D016420
    coding:
      system:
        v: https://www.nlm.nih.gov/mesh
        l: mesh
      code:
        v: D016420
      display:
        v: Comment
      user selected:
        v: false
  citation:
    v: Nat Rev Urol. 2009 May;6(5):250-1. doi: 10.1038/nrurol.2009.56.
  target: Uri
    v: https://pubmed.ncbi.nlm.nih.gov/19424171/
    l: https://pubmed.ncbi.nlm.nih.gov/19424171/
relates to:
  type:
    coding:
      system:
        v: http://terminology.hl7.org/CodeSystem/artifact-relationship-type
        l: artifact-relationship-type
      code:
        v: comment-in
      display:
        v: Has Comment In
  classifier: D016420
    coding:
      system:
        v: https://www.nlm.nih.gov/mesh
        l: mesh
      code:
        v: D016420
      display:
        v: Comment
      user selected:
        v: false
  citation:
    v: Ann Intern Med. 2009 Jun 16;150(12):JC6-6. doi: 10.7326/0003-4819-150-12-200906160-02006.
  target: Uri
    v: https://pubmed.ncbi.nlm.nih.gov/19528551/
    l: https://pubmed.ncbi.nlm.nih.gov/19528551/
relates to:
  type:
    coding:
      system:
        v: http://terminology.hl7.org/CodeSystem/artifact-relationship-type
        l: artifact-relationship-type
      code:
        v: comment-in
      display:
        v: Has Comment In
  classifier: D016420
    coding:
      system:
        v: https://www.nlm.nih.gov/mesh
        l: mesh
      code:
        v: D016420
      display:
        v: Comment
      user selected:
        v: false
  citation:
    v: Eur Urol. 2009 May;55(5):1240. doi: 10.1016/j.eururo.2009.01.059.
  target: Uri
    v: https://pubmed.ncbi.nlm.nih.gov/19650206/
    l: https://pubmed.ncbi.nlm.nih.gov/19650206/
relates to:
  type:
    coding:
      system:
        v: http://terminology.hl7.org/CodeSystem/artifact-relationship-type
        l: artifact-relationship-type
      code:
        v: comment-in
      display:
        v: Has Comment In
  classifier: D016420
    coding:
      system:
        v: https://www.nlm.nih.gov/mesh
        l: mesh
      code:
        v: D016420
      display:
        v: Comment
  target: Uri

v: false

v: Eur Urol. 2009 May;55(5):1239-40. doi: 10.1016/j.eururo.2009.01.058.

published in:
  type:
    coding:
      system:
        v: http://terminology.hl7.org/CodeSystem/published-in-type
        l: published-in-type
      code:
        v: D020492
      display:
        v: Periodical
  identifier:
    type:
      text:
        v: Electronic ISSN Type
    system:
      v: https://portal.issn.org
      l: portal.issn.org
    value:
      v: 1474-547X
  identifier:
    type:
      text:
        v: ISOAbbreviation
    system:
      v: https://www.issn.org/services/online-services/access-to-the-ltwa/
      l: access-to-the-ltwa
    value:
      v: Lancet
  identifier:
    type:
      text:
        v: ISSN Linking
    system:
      v: https://www.issn.org/understanding-the-issn/assignment-rules/the-issn-l-for-publications-on-multiple-media/
      l: the-issn-l-for-publications-on-multiple-media
    value:
      v: 0140-6736
  identifier:
    type:
      text:
        v: Medline Title Abbreviation
    system:
      v: https://www.nlm.nih.gov/tsd/cataloging/contructitleabbre.html
      l: contructitleabbre.html
    value:
      v: Lancet
  identifier:
    type:
      text:
        v: NLM Unique ID
    system:
      v: https://locatorplus.gov/cgi-bin/Pwebrecon.cgi
      l: https://locatorplus.gov/cgi-bin/Pwebrecon.cgi
    value:
      v: 2985213R
  title:
    v: Lancet (London, England)
  publisher location:
    v: England
cited medium:
  coding:
    system:
      v: http://terminology.hl7.org/CodeSystem/cited-medium
      l: cited-medium
    code:
      v: internet
    display:
      v: Internet
volume:
  v: 373
issue:
  v: 9660
article date:
  v: 2009-01-24
page string:
  v: 301-8

v: Electronic

v: Electronic

v: XX

v: Organization identifier

v: XX

v: Organization identifier

v: XX

v: Organization identifier

v: XX

v: Organization identifier

cited medium:
  coding:
    system:
      v: http://terminology.hl7.org/CodeSystem/cited-medium
      l: cited-medium
    code:
      v: internet-without-issue
    display:
      v: Internet without issue
article date:
  v: 2008-12-16

classifier:
  coding:
    system:
      v: http://terminology.hl7.org/CodeSystem/artifact-url-classifier
      l: artifact-url-classifier
    code:
      v: abstract
    display:
      v: Abstract
url:
  v: https://pubmed.ncbi.nlm.nih.gov/19091394/
  l: https://pubmed.ncbi.nlm.nih.gov/19091394/

classifier:
  coding:
    system:
      v: http://terminology.hl7.org/CodeSystem/artifact-url-classifier
      l: artifact-url-classifier
    code:
      v: doi-based
    display:
      v: DOI Based
url:
  v: https://doi.org/10.1016/S0140-6736(08)61815-2
  l: S0140-6736(08)61815-2

type:
  coding:
    system:
      v: http://terminology.hl7.org/CodeSystem/cited-artifact-classification-type
      l: cited-artifact-classification-type
    code:
      v: publishing-model
    display:
      v: Publishing Model
    user selected:
      v: false
classifier:
  coding:
    system:
      v: http://terminology.hl7.org/CodeSystem/citation-artifact-classifier
      l: citation-artifact-classifier
    code:
      v: Print-Electronic
    display:
      v: Print Electronic
    user selected:
      v: false

type:
  coding:
    system:
      v: http://terminology.hl7.org/CodeSystem/cited-artifact-classification-type
      l: cited-artifact-classification-type
    code:
      v: chemical
    display:
      v: Chemical
    user selected:
      v: false
classifier: D000726
  coding:
    system:
      v: https://www.nlm.nih.gov/mesh
      l: mesh
    code:
      v: D000726
    display:
      v: Androgen Antagonists
    user selected:
      v: false
classifier: D005485
  coding:
    system:
      v: https://www.cas.org/support/documentation/chemical-substances
      l: chemical-substances
    code:
      v: 76W6J0943E
    user selected:
      v: false
  coding:
    system:
      v: https://www.nlm.nih.gov/mesh
      l: mesh
    code:
      v: D005485
    display:
      v: Flutamide
    user selected:
      v: false

type:
  coding:
    system:
      v: http://terminology.hl7.org/CodeSystem/cited-artifact-classification-type
      l: cited-artifact-classification-type
    code:
      v: mesh-heading
    display:
      v: MeSH heading
artifact assessment:
  l: meshHeading0
  reference:
    v: #meshHeading0
  type:
    v: ArtifactAssessment
    l: ArtifactAssessment

type:
  coding:
    system:
      v: http://terminology.hl7.org/CodeSystem/cited-artifact-classification-type
      l: cited-artifact-classification-type
    code:
      v: publication-type
    display:
      v: Publication type
classifier: D017428
  coding:
    system:
      v: https://www.nlm.nih.gov/mesh
      l: mesh
    code:
      v: D017428
    display:
      v: Clinical Trial, Phase III
    user selected:
      v: false
classifier: D016428
  coding:
    system:
      v: https://www.nlm.nih.gov/mesh
      l: mesh
    code:
      v: D016428
    display:
      v: Journal Article
    user selected:
      v: false
classifier: D016448
  coding:
    system:
      v: https://www.nlm.nih.gov/mesh
      l: mesh
    code:
      v: D016448
    display:
      v: Multicenter Study
    user selected:
      v: false
classifier: D016449
  coding:
    system:
      v: https://www.nlm.nih.gov/mesh
      l: mesh
    code:
      v: D016449
    display:
      v: Randomized Controlled Trial
    user selected:
      v: false
classifier: D013485
  coding:
    system:
      v: https://www.nlm.nih.gov/mesh
      l: mesh
    code:
      v: D013485
    display:
      v: Research Support, Non-U.S. Gov't
    user selected:
      v: false

type:
  coding:
    system:
      v: http://terminology.hl7.org/CodeSystem/cited-artifact-classification-type
      l: cited-artifact-classification-type
    code:
      v: knowledge-artifact-type
    display:
      v: Knowledge Artifact Type
    user selected:
      v: false
classifier:
  coding:
    system:
      v: http://terminology.hl7.org/CodeSystem/citation-artifact-classifier
      l: citation-artifact-classifier
    code:
      v: D016428
    display:
      v: Journal Article
    user selected:
      v: false
artifact assessment:
  display:
    v: Classifier added by Computable Publishing LLC

type:
  coding:
    system:
      v: http://terminology.hl7.org/CodeSystem/cited-artifact-classification-type
      l: cited-artifact-classification-type
    code:
      v: citation-subset
    display:
      v: Citation subset
    user selected:
      v: false
classifier:
  coding:
    system:
      v: https://www.nlm.nih.gov/bsd/licensee/elements_descriptions.html#citationsubset
      l: citationsubset
    code:
      v: IM
    display:
      v: IM
    user selected:
      v: false

complete:
  v: true
entry:
  contributor:
    l: contributor0
    reference:
      v: #contributor0
    type:
      v: Practitioner
      l: Practitioner
    display:
      v: Widmark A
  forename initials:
    v: A
  affiliation:
    display:
      v: Department of Radiation Sciences, Oncology, Umeå University, Umeå, Sweden.
entry:
  contributor:
    l: contributor1
    reference:
      v: #contributor1
    type:
      v: Practitioner
      l: Practitioner
    display:
      v: Klepp O
  forename initials:
    v: O
entry:
  contributor:
    l: contributor2
    reference:
      v: #contributor2
    type:
      v: Practitioner
      l: Practitioner
    display:
      v: Solberg A
  forename initials:
    v: A
entry:
  contributor:
    l: contributor3
    reference:
      v: #contributor3
    type:
      v: Practitioner
      l: Practitioner
    display:
      v: Damber JE
  forename initials:
    v: JE
entry:
  contributor:
    l: contributor4
    reference:
      v: #contributor4
    type:
      v: Practitioner
      l: Practitioner
    display:
      v: Angelsen A
  forename initials:
    v: A
entry:
  contributor:
    l: contributor5
    reference:
      v: #contributor5
    type:
      v: Practitioner
      l: Practitioner
    display:
      v: Fransson P
  forename initials:
    v: P
entry:
  contributor:
    l: contributor6
    reference:
      v: #contributor6
    type:
      v: Practitioner
      l: Practitioner
    display:
      v: Lund JA
  forename initials:
    v: JA
entry:
  contributor:
    l: contributor7
    reference:
      v: #contributor7
    type:
      v: Practitioner
      l: Practitioner
    display:
      v: Tasdemir I
  forename initials:
    v: I
entry:
  contributor:
    l: contributor8
    reference:
      v: #contributor8
    type:
      v: Practitioner
      l: Practitioner
    display:
      v: Hoyer M
  forename initials:
    v: M
entry:
  contributor:
    l: contributor9
    reference:
      v: #contributor9
    type:
      v: Practitioner
      l: Practitioner
    display:
      v: Wiklund F
  forename initials:
    v: F
entry:
  contributor:
    l: contributor10
    reference:
      v: #contributor10
    type:
      v: Practitioner
      l: Practitioner
    display:
      v: Fosså SD
  forename initials:
    v: SD
entry:
  contributor:
    l: contributor11
    reference:
      v: #contributor11
    type:
      v: Organization
      l: Organization
    display:
      v: Scandinavian Prostate Cancer Group Study 7
entry:
  contributor:
    l: contributor12
    reference:
      v: #contributor12
    type:
      v: Organization
      l: Organization
    display:
      v: Swedish Association for Urological Oncology 3